Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on record review, interview, and policy review, the provider failed to ensure the staff educated the resident or resident's representative of the risk versus benefits of medications or of alternative treatments to make an informed decision for the consent for the use of psychotropic medications (drugs that affects brain activities associated with mental processes and behavior) before they were given for two of two sampled residents (7 and 10). Findings include:1. Review of resident 2's electronic medical record (EMR) revealed that she was admitted to the facility on [DATE]. Her diagnoses included Alzheimer's disease (a progressive and irreversible brain disorder that affects memory, thinking, social abilities, and body functions), unspecified psychosis not due to a substance or known physiological condition, unspecified hallucinations, delusional disorder (false beliefs and distorted views of reality), dementia (a group of symptoms affecting memory, thinking, and social abilities), depression, and anxiety disorder (anticipation of future danger or misfortune with feelings of distress and/or sadness and symptoms such as restlessness or irritability). She was unable to make decisions regarding her medical care, and her son was her power of attorney (POA, a designated person on a legal document to act on behalf of a resident).
On 1/12/26, her mental health provider ordered aripiprazole 5 milligrams (mg) (an atypical antipsychotic medication that alters neurotransmitter activity in the brain to reduce symptoms of mental health conditions) at bedtime for hallucinations (to see, hear, smell, taste, or touch something that is not there). The first dose was given on 1/12/26 at bedtime. There was no documentation that resident 2's POA was notified about the new medication, if risks versus benefits were discussed, or if consent was obtained regarding the use of that psychotropic medication. The aripiprazole was discontinued on 2/11/26 as her hallucinations and other mental health symptoms were continuing without improvement.
2. Review of resident 7's electronic medical record (EMR) revealed that he admitted to the facility on [DATE]. His 2/20/26 Brief Interview for Mental Status (BIMS) assessment score was 3, which indicated his cognition was severely impaired. His diagnoses included anxiety disorder, symptoms and signs involving cognitive functions and awareness, delusional disorder, and dementia with behavioral disturbance.
His 3/12/26 care plan (personalized plan that addresses a resident's care needs, goals, and interventions) had a focus area that read, The resident has potential to be verbally aggressive towards residents and staff r/t [related to] Poor impulse control, with an intervention that read, Keep family and physician updated. Another focus area read, The resident uses antipsychotic medications [a drug that alters neurotransmitter activity in the brain to reduce symptoms of mental health conditions] r/t behavior management with an intervention that read, Discuss with MD [medical doctor], family re [regarding] ongoing need for use of medication. Review behaviors/interventions and alternate therapies attempted and their effectiveness per policy.
A 11/27/24 physician's order for mirtazapine (an antidepressant) 15 mg at bedtime for anxiety was received. There was no documentation that the resident's representative was notified of the new medication order, the indication for the medication, the risk versus benefits of that medication, or alternative treatments to that medication.
On 1/8/25, the mirtazapine dose was ordered to be increased to 30 mg at bedtime. There was a progress note that stated the nurse had attempted to call the resident's representative but there was no answer. There was no further documentation that the nurse reattempted to call the resident's representative or that the resident's representative returned the call.
A 2/5/25 physician's order for sertraline (an antidepressant) 25 mg every day for anxiety was received. A progress note indicated resident 7's representative was notified of the new medication but there was no documentation that the risk versus benefits or alternative treatments were addressed.
On 3/7/25, there was a physician's order to reduce resident 7's mirtazapine to 15 mg for 28 days, then 7.5 mg for 28 days, then 3.75 mg for 14 days, and then to stop the medication due to ineffective behavioral results. Resident 7's representative was documented as having been notified of this change.
On 3/17/25, there was a physician's order to increase resident 7's sertraline to 50 mg daily and started aripiprazole (Abilify, an antipsychotic medication) 5 mg at bedtime for mood and delusions. There was no documentation that the resident's representative was notified of the new medication order, the indication for the medication, the risk versus benefits of that medication, or alternative treatments to that medication.
On 4/3/25, resident 7's mirtazapine was ordered to be continued at 15 mg every day at bedtime, the scheduled reduction of that medication was to be stopped, and his Abilify was increased to 10 mg at bedtime. There was no documentation that the resident's representative was notified of the changed medication orders, the indication for the changes, the risks versus benefits of those medications, or alternative treatments to those medications.
On 4/16/25, resident 7's physician ordered to increase the Abilify to 15 mg at bedtime, decrease his mirtazapine to 7.5 mg for two weeks and then stop, and to increase his sertraline to 75 mg daily for two weeks, then increase it to 100 mg daily. Resident 7's representative was notified of the changed medication orders, but there was no documentation that resident 7's representative was informed of the indication for the changes, the risks versus benefits of those medications, or alternative treatments to those medications.
On 6/24/25, resident 7's sertraline increased to 125 mg daily. Resident 7's representative was notified of the changed medication order, but there was no documentation that resident 7's representative was informed of the indication for the change, the risks versus benefits of the medication, or alternative treatments to the medications.
On 7/17/25, resident 7's physician ordered lorazepam (an antianxiety medication) 0.5 mg every four hours as needed for anxiety and restlessness. There was no documentation that the resident's representative was notified of the new medication order, the indication for the medication, the risks versus benefits of that medication, or alternative treatments to that medication.
On 12/2/25, resident 7's Abilify was decreased to 12.5 mg at bedtime. There was no documentation that resident 7's representative was informed of the changed medication order, the indication for the change, the risks versus benefits of the medication, or alternative treatments to the medications.
On 3/5/26, resident 7's Abilify was decreased to 10 mg at bedtime. There was no documentation that resident 7's representative was informed of the changed medication order, the indication for the change, the risks versus benefits of the medication, or alternative treatments to the medications.
3. Interview on 3/11/26 at 4:36 p.m. with director of nursing (DON) B revealed that written informed consents were not obtained from a resident or resident representative before beginning a psychotropic medication. The residents' medications were reviewed with the resident or their representative upon admitting to the facility and the resident or resident's representative signed that medication list. Neither the medication list nor the residents' baseline care plan addressed the risks versus benefits of psychotropic medications.
4. Interview on 3/12/26 at 1:42 p.m. with licensed practical nurse (LPN) R revealed that when a resident had a new medication order or a change in the dose of a medication, the nurse was to call that resident's representative and notify them of the change. If the resident's representative could not be reached, that nurse would pass that on in her report to the next shift and place the order in a file folder labeled waiting for family. The next shift would then attempt to call the residents' representative to notify them of the medication order.
When LPN R called to notify a resident's representative of a new medication, she reviewed the reason the medication was being ordered, the risks of the medication, and answered any questions the resident's representative had. Once the resident's representative was notified of the new medication or change in the dosage of the medication, the notification was to be documented in the resident's progress notes under the communication with family category.
5. Interview on 3/12/26 at 1:50 p.m. with Minimum Data Set (MDS) registered nurse (RN) E revealed that the nurses were to notify the resident's representative before a psychotropic medication was started. They did not have a consent form for psychotropic medications that contained the medications' risks versus benefits review with the resident's representative. She was not aware that the regulation required the risks versus benefits and alternative treatments to the medication was to be reviewed with the resident or the resident's representative before a psychotropic medication was started.
She expected the staff to document in the resident's progress notes that they had notified the resident's representative when a new medication was started or if there was a change in that medication's dose.
She explained that resident 7's representative was difficult to reach, and he did not call the provider back after he was called. She expected the staff to document any attempts made to contact a resident's representative in that resident's progress notes.
6. Interview on 3/12/26 at 1:57 p.m. with DON B revealed that a resident or the resident's representative was to be notified if there was a new medication ordered, a dose of a current medication was changed, or if a medication was discontinued and that notification was to be documented in a progress note in that resident's EMR. She expected the nurses to discuss the risk versus benefits as well as the reason the psychotropic medication was started, or why the dose of the medication was changed with the resident or the resident's representative.
She stated they did not have a professional reference for the nurses to use when they reviewed the risks versus benefits of the psychotropic medications and alternative treatments.
She mentioned that resident 7's family was difficult to reach at times, but she expected the nurses to document their attempts to reach resident 7's representative in a progress note.
She was not aware that the regulation required the risks versus benefits and alternative treatments to be reviewed with the resident or the resident's representative before a psychotropic medication was started.
7. Further interview on 3/12/26 at 2:35 p.m. and 2:50 p.m. with DON B revealed that resident 2's POA was not too involved with her care. They left voicemails on his contact phone number because he rarely answered their calls. She confirmed that she could not find documentation showing that informed consent was obtained from resident 2's POA regarding the aripiprazole. There currently was no system in place to ensure staff were educating and obtaining informed consents from the residents and their representatives about changes in the residents' care.
8. Review of the provider's 10/5/22 Use of Psychotropic Medication policy revealed that the resident's attending physician was responsible for managing the resident's medications. The policy included that the residents and/or representatives shall be educated on the risks and benefits of psychotropic drug use, as well as alternative treatments/non-pharmacological interventions.
On 1/12/26, her mental health provider ordered aripiprazole 5 milligrams (mg) (an atypical antipsychotic medication that alters neurotransmitter activity in the brain to reduce symptoms of mental health conditions) at bedtime for hallucinations (to see, hear, smell, taste, or touch something that is not there). The first dose was given on 1/12/26 at bedtime. There was no documentation that resident 2's POA was notified about the new medication, if risks versus benefits were discussed, or if consent was obtained regarding the use of that psychotropic medication. The aripiprazole was discontinued on 2/11/26 as her hallucinations and other mental health symptoms were continuing without improvement.
2. Review of resident 7's electronic medical record (EMR) revealed that he admitted to the facility on [DATE]. His 2/20/26 Brief Interview for Mental Status (BIMS) assessment score was 3, which indicated his cognition was severely impaired. His diagnoses included anxiety disorder, symptoms and signs involving cognitive functions and awareness, delusional disorder, and dementia with behavioral disturbance.
His 3/12/26 care plan (personalized plan that addresses a resident's care needs, goals, and interventions) had a focus area that read, The resident has potential to be verbally aggressive towards residents and staff r/t [related to] Poor impulse control, with an intervention that read, Keep family and physician updated. Another focus area read, The resident uses antipsychotic medications [a drug that alters neurotransmitter activity in the brain to reduce symptoms of mental health conditions] r/t behavior management with an intervention that read, Discuss with MD [medical doctor], family re [regarding] ongoing need for use of medication. Review behaviors/interventions and alternate therapies attempted and their effectiveness per policy.
A 11/27/24 physician's order for mirtazapine (an antidepressant) 15 mg at bedtime for anxiety was received. There was no documentation that the resident's representative was notified of the new medication order, the indication for the medication, the risk versus benefits of that medication, or alternative treatments to that medication.
On 1/8/25, the mirtazapine dose was ordered to be increased to 30 mg at bedtime. There was a progress note that stated the nurse had attempted to call the resident's representative but there was no answer. There was no further documentation that the nurse reattempted to call the resident's representative or that the resident's representative returned the call.
A 2/5/25 physician's order for sertraline (an antidepressant) 25 mg every day for anxiety was received. A progress note indicated resident 7's representative was notified of the new medication but there was no documentation that the risk versus benefits or alternative treatments were addressed.
On 3/7/25, there was a physician's order to reduce resident 7's mirtazapine to 15 mg for 28 days, then 7.5 mg for 28 days, then 3.75 mg for 14 days, and then to stop the medication due to ineffective behavioral results. Resident 7's representative was documented as having been notified of this change.
On 3/17/25, there was a physician's order to increase resident 7's sertraline to 50 mg daily and started aripiprazole (Abilify, an antipsychotic medication) 5 mg at bedtime for mood and delusions. There was no documentation that the resident's representative was notified of the new medication order, the indication for the medication, the risk versus benefits of that medication, or alternative treatments to that medication.
On 4/3/25, resident 7's mirtazapine was ordered to be continued at 15 mg every day at bedtime, the scheduled reduction of that medication was to be stopped, and his Abilify was increased to 10 mg at bedtime. There was no documentation that the resident's representative was notified of the changed medication orders, the indication for the changes, the risks versus benefits of those medications, or alternative treatments to those medications.
On 4/16/25, resident 7's physician ordered to increase the Abilify to 15 mg at bedtime, decrease his mirtazapine to 7.5 mg for two weeks and then stop, and to increase his sertraline to 75 mg daily for two weeks, then increase it to 100 mg daily. Resident 7's representative was notified of the changed medication orders, but there was no documentation that resident 7's representative was informed of the indication for the changes, the risks versus benefits of those medications, or alternative treatments to those medications.
On 6/24/25, resident 7's sertraline increased to 125 mg daily. Resident 7's representative was notified of the changed medication order, but there was no documentation that resident 7's representative was informed of the indication for the change, the risks versus benefits of the medication, or alternative treatments to the medications.
On 7/17/25, resident 7's physician ordered lorazepam (an antianxiety medication) 0.5 mg every four hours as needed for anxiety and restlessness. There was no documentation that the resident's representative was notified of the new medication order, the indication for the medication, the risks versus benefits of that medication, or alternative treatments to that medication.
On 12/2/25, resident 7's Abilify was decreased to 12.5 mg at bedtime. There was no documentation that resident 7's representative was informed of the changed medication order, the indication for the change, the risks versus benefits of the medication, or alternative treatments to the medications.
On 3/5/26, resident 7's Abilify was decreased to 10 mg at bedtime. There was no documentation that resident 7's representative was informed of the changed medication order, the indication for the change, the risks versus benefits of the medication, or alternative treatments to the medications.
3. Interview on 3/11/26 at 4:36 p.m. with director of nursing (DON) B revealed that written informed consents were not obtained from a resident or resident representative before beginning a psychotropic medication. The residents' medications were reviewed with the resident or their representative upon admitting to the facility and the resident or resident's representative signed that medication list. Neither the medication list nor the residents' baseline care plan addressed the risks versus benefits of psychotropic medications.
4. Interview on 3/12/26 at 1:42 p.m. with licensed practical nurse (LPN) R revealed that when a resident had a new medication order or a change in the dose of a medication, the nurse was to call that resident's representative and notify them of the change. If the resident's representative could not be reached, that nurse would pass that on in her report to the next shift and place the order in a file folder labeled waiting for family. The next shift would then attempt to call the residents' representative to notify them of the medication order.
When LPN R called to notify a resident's representative of a new medication, she reviewed the reason the medication was being ordered, the risks of the medication, and answered any questions the resident's representative had. Once the resident's representative was notified of the new medication or change in the dosage of the medication, the notification was to be documented in the resident's progress notes under the communication with family category.
5. Interview on 3/12/26 at 1:50 p.m. with Minimum Data Set (MDS) registered nurse (RN) E revealed that the nurses were to notify the resident's representative before a psychotropic medication was started. They did not have a consent form for psychotropic medications that contained the medications' risks versus benefits review with the resident's representative. She was not aware that the regulation required the risks versus benefits and alternative treatments to the medication was to be reviewed with the resident or the resident's representative before a psychotropic medication was started.
She expected the staff to document in the resident's progress notes that they had notified the resident's representative when a new medication was started or if there was a change in that medication's dose.
She explained that resident 7's representative was difficult to reach, and he did not call the provider back after he was called. She expected the staff to document any attempts made to contact a resident's representative in that resident's progress notes.
6. Interview on 3/12/26 at 1:57 p.m. with DON B revealed that a resident or the resident's representative was to be notified if there was a new medication ordered, a dose of a current medication was changed, or if a medication was discontinued and that notification was to be documented in a progress note in that resident's EMR. She expected the nurses to discuss the risk versus benefits as well as the reason the psychotropic medication was started, or why the dose of the medication was changed with the resident or the resident's representative.
She stated they did not have a professional reference for the nurses to use when they reviewed the risks versus benefits of the psychotropic medications and alternative treatments.
She mentioned that resident 7's family was difficult to reach at times, but she expected the nurses to document their attempts to reach resident 7's representative in a progress note.
She was not aware that the regulation required the risks versus benefits and alternative treatments to be reviewed with the resident or the resident's representative before a psychotropic medication was started.
7. Further interview on 3/12/26 at 2:35 p.m. and 2:50 p.m. with DON B revealed that resident 2's POA was not too involved with her care. They left voicemails on his contact phone number because he rarely answered their calls. She confirmed that she could not find documentation showing that informed consent was obtained from resident 2's POA regarding the aripiprazole. There currently was no system in place to ensure staff were educating and obtaining informed consents from the residents and their representatives about changes in the residents' care.
8. Review of the provider's 10/5/22 Use of Psychotropic Medication policy revealed that the resident's attending physician was responsible for managing the resident's medications. The policy included that the residents and/or representatives shall be educated on the risks and benefits of psychotropic drug use, as well as alternative treatments/non-pharmacological interventions.